Mycophenolate Mofetil Hexal (Mycophenolate Mofetil)

Mycophenolate Mofetil is an antimetabolite immunosuppressant that inhibits lymphocyte proliferation in transplant and autoimmune disease settings.

• Solid organ transplantation: prevents acute rejection and supports graft survival.
• Lupus nephritis: reduces renal inflammation and preserves kidney function.
• Proliferative glomerulonephritis: controls disease activity and slows progression.

• Mycophenolate Mofetil selectively inhibits inosine monophosphate dehydrogenase (IMPDH), the enzyme required for de novo synthesis of guanosine nucleotides. By depleting guanosine pools, it blocks proliferation of activated T‑ and B‑lymphocytes, which rely on this pathway, while sparing resting cells that can use salvage pathways. This targeted suppression of lymphocyte replication underlies its immunosuppressive effect in transplantation and autoimmune disorders and contributes to reduced immune‑mediated tissue injury.

Mycophenolate Mofetil may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Gastrointestinal upset: nausea, vomiting, diarrhea, or abdominal pain.
• Infections: increased susceptibility to bacterial, viral, or fungal infections.
• Hematologic changes: anemia, leukopenia, or thrombocytopenia.
• Headache: mild to moderate intensity.
• Elevated liver enzymes: transient increases in transaminases.
• Fever: low‑grade fever may occur.
• Rash: mild skin eruptions.

Serious or Rare Side Effects

• Severe infection: opportunistic infections such as Pneumocystis jirovecii pneumonia.
• Progressive multifocal leukoencephalopathy (PML): rare demyelinating brain disease.
• Malignancy: increased risk of post‑transplant lymphoproliferative disorder.
• Bone marrow failure: aplastic anemia or pancytopenia.
• Reproductive